Takahide Nejo, Lin Wang, Kevin K Leung, Albert Wang, Senthilnath Lakshmanachetty, Marco Gallus, Darwin W Kwok, Chibo Hong, Lee H Chen, Diego A Carrera, Michael Y Zhang, Nicholas O Stevers, Gabriella C Maldonado, Akane Yamamichi, Payal B Watchmaker, Akul Naik, Anny Shai, Joanna J Phillips, Susan M Chang, Arun P Wiita, James A Wells, Joseph F Costello, Aaron A Diaz, Hideho Okada
Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter- and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative sources to expand the repertoire of targetable (neo-)antigens and improve therapeutic outcomes. Accumulating evidence suggests that tumor-specific alternative splicing (AS) could be an untapped reservoir of antigens. In this study, we investigated tumor-specific AS events in glioma, focusing on those predicted to generate major histocompatibility complex (MHC)-presentation-independent, cell-surface antigens that could be targeted by antibodies and chimeric antigen receptor-T cells...
March 16, 2024: Scientific Reports